News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Wall Street Zen has upgraded Cardiol Therapeutics (NASDAQ:CRDL) from a "Sell" to a "Hold" rating, aligning with the overall average "Hold" rating from analysts and an $8.50 price target. CRDL shares rose 5.3% to $1.80, with a market cap of $208.6 million, and the company reported a quarterly EPS of -$0.04, outperforming consensus estimates. Institutional investors collectively own …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Cardiol Therapeutics (NASDAQ:CRDL) recently announced its quarterly earnings, reporting an EPS of ($0.04), which surpassed analyst expectations of ($0.09) by $0.05. Following the announcement, the company's shares increased by 1.3% to $1.52, with a market capitalization of approximately $176.15 million. Analyst sentiment for CRDL …
Sharemaestro market context Trend signal active 52 weeks +54.9% · Next-week setup negative 39.8%* Cardiol Therapeutics press release [https://seekingalpha.com/filing/309942772] (CRDL:CA [https://seekingalpha.com/symbol/CRDL:CA]): Q2 GAAP EPS of -C$0.05. MORE ON CARDIOL THERAPEUTICS * Historical earnings data for Cardiol Therapeutics [https://seekingalpha.com/symbol/CRDL:CA/earnings] * Financial information for Cardiol Therapeutics [https://seekingalpha.com/symbol/CRDL:CA/income-statement]
Sharemaestro market context Trend signal active 52 weeks +54.9% · Next-week setup negative 39.8%Cardiol Therapeutics (TSX:CRDL) is a clinical-stage life sciences company focused on developing therapies for cardiovascular conditions, with its research strategy centered on addressing unmet therapeutic needs in this area. The company's future hinges on clinical execution, regulatory developments, and the quality of its trial …
Cardiol Therapeutics is nearing a crucial Phase III readout for its lead drug, CardiolRx, in recurrent pericarditis. The company presented its clinical and commercial strategy at Canaccord Genuity's 46th Annual Growth Conference, highlighting the drug's potential, market opportunity, and positive payer feedback. Despite the …
Cardiol Therapeutics (CRDL) is anticipated to release its Q2 2026 earnings on Thursday, August 13th, with analysts forecasting a loss of $0.09 per share. The company's previous quarter reported a loss of $0.07 per share, meeting estimates. CRDL shares opened at $1.34, and analysts …
Sharemaestro market context Trend signal active 52 weeks +54.9% · Next-week setup negative 39.8%Cardiol Therapeutics (TSX: CRDL) saw its stock climb 3.66% during the latest trading session, driven by renewed investor interest in the biotechnology sector. The company, which focuses on developing therapies for cardiovascular diseases, benefited from optimism surrounding innovative clinical development and increasing healthcare investment. …
Cardiol Therapeutics is increasing its presence in the healthcare sector by showcasing its late-stage cardiovascular research at the B. Riley Summit. The company is focused on developing anti-inflammatory and anti-fibrotic therapies to address unmet needs in heart disease. The article highlights Cardiol Therapeutics' commitment …
Sharemaestro market context Trend signal active 52 weeks +54.9% · Next-week setup negative 39.8%H.C. Wainwright has reiterated a Buy rating for Cardiol Therapeutics (NASDAQ:CRDL) with a $9.00 price target. This re-affirmation follows the publication of the MAvERIC-Pilot study in the Journal of the American Heart Association, which showed positive results for CardiolRx in treating pericarditis. The firm …
Sharemaestro market context Trend signal active 52 weeks +54.9% · Next-week setup negative 39.8%Search by ticker symbol or company name and select a result to open its chart.